共 50 条
- [1] Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaLEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2777 - 2784Patel, Kishan K.Parker, TerriDi, MengyangBar, NoffarHuntington, Scott F.Giri, Smith
- [2] Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston StudyBLOOD, 2020, 136Mateos, MariaGavriatopoulou, MariaFacon, ThierryAuner, Holger W.Leleu, XavierHajek, RomanDimopoulos, Meletios A.Delimpasi, SosanaSimonova, MaryanaSpicka, IvanPour, LudekKryachok, IrinaPylypenko, HalynaDoronin, Vadim A.Usenko, GannaBenjamin, ReubenDolai, Tuphan KantiSinha, Dinesh KumarVenner, Christopher P.Garg, MamtaStevens, Don A.Quach, HangJagannath, SundarMoreau, PhilippeLevy, MosheBadros, Ashraf Z.Anderson, Larry D., Jr.Bahlis, Nizar J.Cavo, MicheleChai, YiArazy, MelinaShah, JatinShacham, SharonKauffman, Michael G.Richardson, Paul G.Grosicki, Sebastian
- [3] Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston StudyBLOOD, 2020, 136Richard, ShambaviChari, AjaiDelimpasi, SosanaSimonova, MaryanaSpicka, IvanPour, LudekKryachok, IrinaDimopoulos, Meletios A.Pylypenko, HalynaAuner, Holger W.Leleu, XavierDoronin, Vadim A.Usenko, GannaHajek, RomanBenjamin, ReubenDolai, Tuphan KantiSinha, Dinesh KumarVenner, Christopher P.Garg, MamtaStevens, Don A.Quach, HangJagannath, SundarMoreau, PhilippeLevy, Moshe Y.Badros, Ashraf Z.Anderson, Larry D., Jr.Bahlis, Nizar J.Facon, ThierryMateos, Maria-VictoriaCavo, MicheleChang, HuaLandesman, YosefJoshi, Anita A.Chai, YiArazy, MelinaShah, JatinShacham, SharonKauffman, Michael G.Grosicki, SebastianRichardson, Paul G.
- [4] Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston StudyBLOOD, 2020, 136Auner, Holger W.Gavriatopoulou, MariaDelimpasi, SosanaSimonova, MaryanaSpicka, IvanPour, LudekDimopoulos, Meletios A.Kryachok, IrinaPylypenko, HalynaLeleu, XavierDoronin, Vadim A.Usenko, GannaHajek, RomanBenjamin, ReubenDolai, Tuphan KantiSinha, Dinesh KumarVenner, Christopher P.Garg, MamtaStevens, Don A.Quach, HangJagannath, SundarMoreau, PhilippeLevy, Moshe Y.Badros, Ashraf Z.Anderson, Larry D., Jr.Bahlis, Nizar J.Facon, ThierryMateos, MariaCavo, MicheleJoshi, Anita A.Chai, YiArazy, MelinaShah, JatinShacham, SharonKauffman, Michael G.Richardson, Paul G.Grosicki, Sebastian
- [5] Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston StudyBLOOD, 2020, 136Mateos, MariaJagannath, SundarDelimpasi, SosanaSimonova, MaryanaSpicka, IvanPour, LudekKryachok, IrinaGavriatopoulou, MariaDimopoulos, Meletios A.Pylypenko, HalynaAuner, Holger W.Leleu, XavierDoronin, Vadim A.Usenko, GannaBenjamin, ReubenDolai, Tuphan KantiSinha, Dinesh KumarVenner, Christopher P.Garg, MamtaStevens, Don A.Quach, HangMoreau, PhilippeLevy, Moshe Y.Badros, Ashraf Z.Anderson, Larry D., Jr.Bahlis, Nizar J.Facon, ThierryCavo, MicheleChai, YiArazy, MelinaShah, JatinShacham, SharonKauffman, Michael G.Richardson, Paul G.Grosicki, Sebastian
- [6] Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON studyAMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E83 - E86Delimpasi, SosanaMateos, Maria VictoriaAuner, Holger W.Gavriatopoulou, MariaDimopoulos, Meletios A.Quach, HangPylypenko, HalynaHajek, RomanLeleu, XavierDolai, Tuphan KantiSinha, Dinesh KumarVenner, Christopher P.Benjamin, ReubenGarg, Mamta KrishnanDoronin, VadimLevy, YairMoreau, PhilippeChai, YiArazy, MelinaShah, JatinShacham, SharonKauffman, Michael G.Richardson, Paul G.Grosicki, Sebastian
- [7] Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Walker, Christopher JamesLi, ShirongChai, YiShah, Jatin J.Shacham, SharonLentzsch, SuzanneLandesman, Yosef
- [8] COST-EFFECTIVENESS OF ONCE WEEKLY SELINEXOR-BORTEZOMIB-DEXAMETHASONE (XVD) IN PREVIOUSLY TREATED MULTIPLE MYELOMA (MM)VALUE IN HEALTH, 2021, 24 : S34 - S34Dolph, M.Tremblay, G.Leong, H.
- [9] Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myelomaJournal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32 : 495 - 500Yadan WangLisha AiGuohui CuiBhuveshwarnath GowreaMian LiYu Hu
- [10] Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myelomaJOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2012, 32 (04) : 495 - 500Wang, YadanAi, LishaCui, GuohuiGowrea, BhuveshwarnathLi, MianHu, Yu